Montelukast's effect on kidney and vascular health in type 1 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of montelukast, a leukotriene receptor antagonist, on kidney and cardiovascular function in individuals with type 1 diabetes who exhibit early signs of kidney disease, specifically albuminuria. Participants will be randomized to receive either montelukast or a placebo, and the primary outcome will be the reduction of protein levels in urine, which indicates kidney function. The study aims to determine if targeting inflammation can slow the progression of diabetic kidney disease. Eligible participants include adults aged 18-80 with a history of type 1 diabetes and specific kidney function parameters.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-80 years
* Type 1 diabetes for at least 5 years
* Urine albumin to creatinine ratio 30-5000 mg/g on first morning void
* eGFR 30-89 ml/min/1.73m2 at time of screening
* Blood pressure \<140/90 mm Hg prior to randomization
* Use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker with stable dose for 4 weeks
* BMI \< 40 kg/m2 (FMDBA measurements can be inaccurate in severely obese patients).
* Stable anti-hypertensive regimen for at least one month prior to randomization
* Stable regimen of insulin delivery, i.e. automated insulin delivery (AID) system or multiple daily injections) 4 weeks prior to randomization
* Sedentary or recreationally active (≤2 days of vigorous aerobic exercise as vigorous exercise may affect vascular function measurements)
* Able to provide consent

Exclusion Criteria:

* Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year
* Uncontrolled hypertension
* Factors judged to limit adherence to interventions
* Anticipated initiation of dialysis or kidney transplantation within 6 months
* Current participation in another research study
* Pregnancy or planning to become pregnant or currently breastfeeding
* Allergy to aspirin
* Severe hepatic impairment (Child-Pugh Class C)
* History of major psychiatric disorder
* Use of inhaled or systemic corticosteroids or long-acting beta agonists (higher risk of neuropsychiatric reaction)
* Penicillin allergy
* Iodine allergy
* Shellfish allergy
* Current use of phenobarbital, rifampin or carbamazepine

Where it's running

• University of Colorado Anschutz Medical Campus
  Aurora, Colorado, United States Recruiting

Study contacts

• Principal investigator: Jessica Kendrick, MD — University of Colorado Denver | Anschutz
• Study coordinator: Jessica Kendrick
• Email: Jessica.Kendrick@cuanschutz.edu
• Phone: 3037244837

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dapagliflozin to lower albuminuria in adolescents with early chronic kidney disease

  We will test whether a once-daily 10 mg dapagliflozin pill lowers urine albumin in 14–18-year-olds from Aguascalientes who have early chronic kidney disease and persistent microalbuminuria.

  Recruiting Phase 4 Centenario Hospital Miguel Hidalgo · Aguascalientes, Aguascalientes · NCT07405216

• Empagliflozin to protect kidney function in sickle cell anemia with albuminuria

  This study tests whether taking empagliflozin can slow kidney decline in people with sickle cell anemia and albuminuria.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT07175051

• Algae supplements for heart risk markers and gut health

  This trial will test whether daily supplements of spirulina or Gelidium corneum change gut microbes and improve heart‑disease risk markers in adults over 50 with cardiovascular disease, diabetes, or related conditions.

  Recruiting Universidade do Porto · Porto · NCT07173062

• Understanding chronic kidney disease in Sub-Saharan Africa

  This study is trying to understand how common chronic kidney disease is in Sub-Saharan Africa and what factors might be causing it by looking at the health and lifestyle of adults in the Bagamoyo district.

  Recruiting Swiss Tropical & Public Health Institute · Bagamoyo, Pwani Region · NCT05881447

• Understanding Diabetic Kidney Disease in Patients with Type 2 Diabetes

  This study is trying to understand how kidney disease affects people with Type 2 diabetes and macroalbuminuria by looking at their kidney samples and other health markers over 20 years to improve treatment options.

  Recruiting at 13 sites Herlev Hospital · Skejby, Aarhus and 12 other locations · NCT04916132

• Understanding pediatric hypertension and its effects on the body

  This study looks at how different factors related to blood pressure affect children aged 7-18 who have just been diagnosed with high blood pressure, to see how it impacts their health over two years.

  Recruiting Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT04752293

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.